MDP has succesfully completed with Joset Asset for 2 weeks

MDP has succesfully completed with Joset Asset for 2 weeks

MDP has succesfully completed with Joset Asset for 2 weeks.

Test preparation: Joset Asset, tablets, film-coated (INN: Ambroxol, guaifenesin, salbutamol).

The comparator: Ascoril®, tablets (INN: Bromhexine, guaifenesin, salbutamol).

Inclusion criteria:

  1. A signed Information sheet patient consent form for participation in the study.
  2. Age from 18 to 65 years inclusive.
  3. Men and women.
  4. The diagnosis of acute respiratory tract infections, uncomplicated established no earlier than 1 day before screening, in accordance with codes in ICD-10: Acute upper respiratory tract infection multiple and unspecified sites (J06), Influenza caused by a identified influenza virus (J10) Influenza, virus not identified (J11), Acute respiratory lower respiratory infection unspecified (J22).
  5. Cough (dry or productive) intensity 3-5 points on the Point scale assessment of cough intensity.
  6. For women, negative pregnancy test.
  7. Assent to adequate contraceptive methods (barrier methods of contraception hormonal contraceptives, spermicides) for the entire period of participation in the study.
  8. The ability of the patient, according to the researcher, to follow all the requirements of the Protocol.

Exclusion criteria:

  1. Allergic history or individual intolerance to the components of the studied drugs.
  2. The presence of concomitant severe decompensated somatic diseases: disorders of the cardiovascular system (arterial hypertension, aortic stenosis, tachyarrhythmia, heart failure, etc.), pathology of the respiratory system (cystic fibrosis, COPD, asthma), gastrointestinal tract (gastric ulcer, duodenal ulcer, etc.), kidney and urinary tract (chronic renal failure, etc.), liver and biliary tract (hepatic insufficiency), endocrine system (hyperthyroidism, diabetes, pheochromocytoma, etc.) pathology of the organ of vision (glaucoma).
  3. Malignant neoplasms (except basal cell carcinoma or cured cancer in situ in history).
  4. Tuberculosis or TB suspicion at the time of inclusion or in history.
  5. Suspected pneumonia.
  6. The need for hospitalization for medical reasons.
  7. Receiving β2-adrenomimetic drugs, corticosteroids (systemic or local), cytotoxic agents, bronchodilators, non-selective beta blockers, antihypertensive drugs, MAO inhibitors, CNS stimulants, thyroid hormones, theophylline and ephedrine, PG synthesis inhibitors, tricyclic antidepressants, antihypertensive drugs, nitrates, cardiac glycosides, antibiotics.
  8. The positive result of tests for HIV, syphilis, hepatitis b and C.
  9. Anamnestic information about alcoholism, drug abuse, abuse of medicines.
  10. Pregnancy and breast-feeding.
  11. Participation in a clinical study of drugs in less than 3 months before inclusion in the present study.

 

Comments are closed.